Page 13 - 2021_05-Haematologica-web
P. 13
Editorials
phoid disease itself and be indicative of worsening bone marrow infiltration by aberrant cells and consequent megakaryocyte hypoplasia and/or dysplasia or be indica- tive of dysregulated immunity leading to ITP, thus not necessarily indicating a worse prognosis, as shown in the study by Jachiet et al.1 Hence, in these circumstances, sep- arating ITP, diagnosed with bona fide criteria, from non- immune thrombocytopenia may be of clinical relevance for both the patient and the treating physician.
In conclusion, the report by Jachiet et al.1 opens new perspectives for a deeper understanding of the pathobio- logical mechanisms linking ITP and some clonal myeloid/lymphoid disorders and of their temporal associ- ation. This will require the collection of large prospective series of patients with either or both disorders and their investigation with extensive next-generation sequencing technology and better immunophenotyping of the cellu- lar components involved. In the meantime, the practicing hematologist should be aware of the difficulties and of the importance of separating ITP from the thrombocy- topenia inherent to the defective megakaryopoiesis of these preleukemic disorders.
Disclosures
No conflicts of interest to disclose
References
1. Jachiet V, Moulis G, Hadjadj J, et al. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica. 2021;106(5):1414-1422.
2.Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
3. Pfeilstocker M, Tuechler H, Sanz G, et al. Time-dependent changes
in mortality and transformation risk in MDS. Blood. 2016;128(7):
902-910.
4.Bourgeois E, Caulier MT, Rose C, Dupriez B, Bauters F, Fenaux P.
Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia. 2001;15(6):950-953.
5.Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune dis- eases and myelodysplastic syndromes. Am J Hematol. 2016;91(5): E280-283.
6. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22): 3308-3315.
7. Hadjadj J, Michel M, Chauveheid MP, Godeau B, Papo T, Sacre K. Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93(6):521-526.
8. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. 1975-2017.
9. Ambinder AJ, Miller J, DeZern AE. Autoimmune disease in CMML- the chicken or the egg? Best Pract Res Clin Haematol. 2020;33(2): 101136.
10. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic ane- mia and immune thrombocytopenic purpura. Haematologica. 2008;93(1):151-152.
11. Visco C, Rodeghiero F, Romano A, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disor- ders: a phase 2 multicenter study. Blood. 2019;134(20):1708-1711.
12.Rossi D, De Paoli L, Franceschetti S, et al. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. Br J Haematol. 2007;138(2):249-252.
13. Tinazzi E, Osti N, Beri R, et al. Pathogenesis of immune thrombocy- topenia in common variable immunodeficiency. Autoimmun Rev. 2020;19(9):102616.
14. Valent P. ICUS, IDUS, CHIP and CCUS: diagnostic criteria, separa- tion from MDS and clinical implications. Pathobiology. 2019;86(1):30-38.
15.DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book. 2019;39:400-410.
haematologica | 2021; 106(5)
1233
